Wart

Researchers are studying a rare genetic condition called WHIMS, which causes severe neutropenia, a low white blood cell count that makes it harder for the body to fight infections. WHIMS leads to serious infections and complications like warts and cancers related to human papillomavirus (HPV). This research aims to evaluate the safety and effectiveness of a drug called Mozobil in treating neutropenia in people with WHIMS, exploring doses within the approved range. Participants will receive Mozobil through twice daily subcutaneous injections or continuous infusion using a pump. The study includes a dose escalation phase where doses increase over five days until white blood cell counts improve or the maximum dose is reached. After this, patients may enter a long-term phase receiving Mozobil once or twice daily for up to five years. Treatment will be paused for two days before starting Mozobil if participants are on certain white blood cell stimulating medications. During the study, participants will undergo medical history reviews, physical exams, lung and heart function tests, and blood and urine sampling to monitor safety and effectiveness. Researchers will track white blood cell levels, infection rates, and HPV-related skin lesions. Participants will also provide samples for further analysis and adhere to contraception requirements if applicable. The study may last up to seven years, with ongoing safety and response monitoring throughout.

Researchers are evaluating the effectiveness of two treatments, bleomycin injection and cryotherapy, for plantar warts (Verruca Plantaris). This randomized controlled trial aims to compare how well these treatments work using dermoscopy, as well as assess their safety, economic impact, and effects on quality of life. The study includes adult participants aged 18 to 65 years with diagnosed plantar warts. Participants are randomly assigned to one of two groups: the Bleomycin Group or the Cryotherapy Group. The bleomycin treatment involves injecting a diluted solution directly into the wart based on its size, while the cryotherapy treatment uses liquid nitrogen to freeze the wart twice with a 30-second interval. The effectiveness of each treatment is evaluated two weeks after the treatment ends. During the study, patients will undergo assessments including dermoscopic examination of the warts and photographic documentation of the lesions. Researchers will monitor the complete clearance rate of warts as the primary outcome. Safety and other impacts such as quality of life and cost will also be tracked. The total study duration and specific visit schedules are based on treatment and follow-up timelines ending in mid-2025.

Researchers are studying the safety and effectiveness of Candida antigen and bivalent HPV vaccine in treating common warts. The trial compares these treatments given alone or combined to see how well they clear warts and prevent recurrence. This is a Phase 2 randomized study involving patients with multiple warts. Participants are divided into three groups: one receives Candida antigen injections directly into the largest wart, another receives bivalent HPV vaccine injections, and the third group receives both treatments together. Injections are given every two weeks for up to five sessions or until the warts clear. During the study, patients will be monitored for complete, partial, or no response to treatment over three months. Researchers will also follow up for six months after recovery to check for wart recurrence. Assessments include clinical evaluation of warts and treatment safety throughout the trial.

Researchers are evaluating the safety and effectiveness of YCANTH (VP-102), a topical treatment, for people with common warts (verruca vulgaris) in a Phase 3 clinical trial called COVE-2. This study compares the active treatment to a placebo (vehicle) and includes participants aged 2 years and older who have at least one treatable common wart. The study aims to understand if YCANTH can clear all treatable warts by the end of the treatment period. The trial includes a Screening Period of up to 60 days, followed by a 75-day Treatment Period and a 63-day Follow-up Period. Participants receive topical applications of YCANTH (VP-102) or a placebo every 21 days, up to four treatments. The study drug is applied to warts and a small area of surrounding skin, then covered with occlusive tape overnight. Wart paring may be done before application if needed. Warts are treated completely unless limited by the number of applicators. After each treatment, participants have in-person or telephone follow-ups to assess wart clearance and skin reactions. During the study, participants attend visits for dermatologic exams, wart measurements, and treatment assessments. Follow-up includes visual checks for complete wart clearance, monitoring of local skin reactions, adverse events, and medication use. Even if warts clear early, participants continue scheduled visits until the study ends. After this study, participants may join a long-term follow-up study to further evaluate YCANTH for up to 54 weeks. The primary outcome is the proportion of participants with complete clearance of all treatable warts by Day 84.

Idiopathic CD4+ lymphocytopenia (ICL) is a condition marked by low levels of CD4+ T cells, which can increase the risk of infections, autoimmune diseases, and cancers. Researchers aim to understand the natural history of ICL by examining how CD4+ counts change over time, the onset of related infections and autoimmune issues, and possible genetic causes. The study also looks at the immune system status of patients and how it relates to disease development. The study involves patients with confirmed ICL, their blood relatives, and household contacts. Participants receive standard care to manage opportunistic infections. Initial visits include medical history, physical exams, blood tests, urine tests, and specialized evaluations as needed. Follow-up visits occur about once a year and continue for 4 to 10 years to monitor immune function and disease progression. Participants will undergo regular blood tests to measure CD4+ T cell counts and other immune markers, along with physical and rheumatology exams. Researchers will collect samples for immunologic, genetic, and microbiome analyses. The primary measure is CD4+ T cell count, tracked annually. The study monitors the effects of ICL over time and the relationship between immune status and infections or other conditions.

Researchers are evaluating the use of the human papillomavirus (HPV) vaccine for treating refractory cutaneous warts, which are common skin growths that can be painful, persistent, and difficult to treat. This randomized, double-blinded, placebo-controlled trial aims to determine if HPV vaccination can be an effective therapy for these stubborn warts, as current treatments often fail and warts can cause significant discomfort and distress. Participants will be randomly assigned to receive either the 9-valent HPV vaccine or a placebo. Injections are given as a 0.5-mL intramuscular dose at weeks 0, 4, and 20. The study includes 120 participants and follows them for 24 weeks to assess the vaccine's effect on wart resolution and participants' quality of life. During the trial, participants will have regular evaluations including assessments of their wart response at 4, 8, and 24 weeks after the first dose. Quality of life will be measured at multiple time points using the Skindex-16 questionnaire. Safety will be monitored throughout the study by recording any adverse events. The entire study duration for participants is 24 weeks, during which they will attend scheduled visits for injections and evaluations.

Researchers are investigating the use of hyperthermia treatment combined with microneedle patches to improve the treatment of viral warts. Hyperthermia involves raising the temperature of the skin to about 44 6C, which may help activate the body's immune response to clear HPV-infected lesions. This study compares three groups: hyperthermia alone, hyperthermia with a microneedle patch loaded with saline, and hyperthermia with a hydrogen peroxide microneedle patch to enhance treatment effects. Participants will be randomly assigned to receive one of the three treatments. Hyperthermia is applied to a selected wart for 30 minutes per session, with three sessions in the first week, two in the second, and two in the third week. The microneedle patches, either loaded with saline or hydrogen peroxide, are applied daily for one hour over six weeks. The study follows a randomized, parallel-group, assessor-blinded design with adaptive sample size adjustments based on interim results. During the study, participants will undergo treatment sessions and follow-up visits to monitor wart clearance and recurrence. Researchers will assess complete wart clearance rates, time to clearance, recurrence within six months, changes in wart size and number, pain during treatment, and any adverse events. The entire evaluation period includes treatment and six months of follow-up to gather comprehensive safety and efficacy data.

This clinical trial studies whether injecting acyclovir or vitamin D3 directly into skin warts helps clear them in people aged 12 and older who have common, plantar, flat, or periungual warts. It aims to find out if either treatment leads to complete wart clearance by week 8, which treatment works better, and what side effects occur. The trial is a Phase 4 study comparing two treatment groups with 20 participants each. Participants receive injections of either acyclovir or vitamin D3 into the wart every two weeks for up to four sessions. The dose varies by wart size, with injections given at the start and repeated biweekly. Both treatments are delivered directly into the wart lesion. This comparison helps researchers evaluate the effectiveness and safety of these two intralesional therapies. During the study, participants will have photographs taken of their warts before treatment and at every visit. Clinic visits include measuring the size and number of warts. After treatment, participants are followed for up to three months to monitor wart recurrence and any side effects. The main outcome measured is wart clearance at week 8, with additional tracking of early recurrence, adverse effects, and number of treatment sessions needed.

Researchers are evaluating the long-term safety and effectiveness of a treatment called YCANTH (also known as VP-102 or TO-208) for people with common warts who previously participated in related studies (COVE-2 or COVE-3). This phase 3, open-label study aims to monitor side effects, including expected local skin reactions, and to assess how well repeated applications of YCANTH clear common warts over time. Participants with warts at the start of the study will receive YCANTH applied directly to each wart every 21 days, up to four additional treatments or until all warts clear. After clearance, participants will have observation visits every 42 days without treatment, but if new warts appear, treatment will resume. The study includes careful wart preparation, application of the drug with occlusive tape overnight, and monitoring of skin reactions. The entire study lasts approximately 294 days from parent study completion to the final visit on Day 378. Throughout the study, participants will attend treatment and observation visits where researchers will evaluate wart clearance, skin reactions, vital signs, and medication use. Detailed assessments include wart counts, photographic documentation for those who consent, and monitoring for adverse events. Participants must follow study instructions, including limiting certain water exposures after treatment, and will be observed until the study ends on Day 378.

This research aims to evaluate the effectiveness and safety of hyperthermia treatment for viral warts in special populations, including pregnant women, children, patients with autoimmune diseases, diabetes, and those on immunosuppressants after organ transplantation. Hyperthermia, a treatment using temperatures above normal body temperature, has shown promise in early studies by activating the body's immune response to remove HPV infection lesions. Prior research by this group indicated a 45-55% cure rate with hyperthermia, with benefits like no trauma, low recurrence, and good tolerance, leading to inclusion in medical guidelines and device registration for national promotion. The study uses an infrared hyperthermia device set at 44±1°C applied to lesions. Treatment involves three consecutive days of 30-minute sessions, followed by a break of 7-10 days, then two consecutive days of treatment, and subsequent sessions every 7-10 days. Lesion changes are assessed after 15 treatments to monitor the response to therapy. Participants will be monitored for cure and recurrence rates at three and six months, alongside rates of any adverse reactions. The study is conducted in multiple centers with real-world settings, focusing on this special population with viral warts. The total treatment and follow-up duration allow for assessing both short-term and longer-term outcomes of hyperthermia therapy for wart removal.